CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
688193 Shanghai Rendu Biotechnology
- 37.00
- +1.20+3.35%
Market Closed Apr 30 15:00 CST
1.48BMarket Cap-143.97P/E (TTM)
37.02High36.01Low3.74KlotVolume36.18Open35.80Pre Close13.64MTurnover1.18%Turnover RatioLossP/E (Static)40.00MShares50.3052wk High1.62P/B1.17BFloat Cap22.9052wk Low42.96Limit Up31.57MShs Float71.58Historical High28.64Limit Down2.82%Amplitude22.21Historical Low0.30Dividend TTM36.52Avg Price1.24KlotAsk0.81%Div YieldTTM100Lot Size2.38KlotBid
Shanghai Rendu Biotechnology Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -9.22%40.68M | 7.87%177.35M | 11.57%130.64M | 8.31%86.68M | 15.60%44.82M | -45.89%164.41M | -51.23%117.1M | -52.83%80.03M | -58.44%38.77M | 3.95%303.85M |
| Operating revenue | -9.22%40.68M | 7.87%177.35M | 11.57%130.64M | 8.31%86.68M | 15.60%44.82M | -45.89%164.41M | -51.23%117.1M | -52.83%80.03M | -58.44%38.77M | 3.95%303.85M |
| Total operating cost | 0.96%44.16M | 4.01%189.59M | 0.76%135.83M | -9.07%88.42M | -9.55%43.74M | -37.24%182.29M | -38.98%134.81M | -33.94%97.24M | -33.93%48.36M | 27.94%290.47M |
| Operating cost | 8.88%9.49M | 18.05%36.38M | 19.67%25.62M | 10.65%16.42M | 14.80%8.71M | -70.58%30.82M | -70.79%21.41M | -72.62%14.84M | -73.63%7.59M | 41.20%104.74M |
| Operating tax surcharges | 26.54%309.75K | 4.37%1.01M | 5.51%739.81K | 5.12%493.8K | 12.38%244.78K | -19.63%965.11K | -18.96%701.2K | -31.80%469.75K | -53.98%217.82K | 44.87%1.2M |
| Operating expense | -0.66%20.12M | -0.97%89.86M | -6.42%63.48M | -19.55%41.48M | -22.37%20.26M | -26.47%90.74M | -32.78%67.84M | -21.76%51.55M | -14.12%26.09M | 21.72%123.4M |
| Administration expense | -11.77%6.37M | 9.84%29.4M | 2.92%21.66M | -3.52%13.99M | 1.24%7.22M | -14.58%26.77M | -7.43%21.04M | 7.90%14.5M | 8.74%7.14M | 21.38%31.34M |
| Financial expense | 86.78%-380.15K | 23.49%-6.23M | 3.86%-5.66M | -70.10%-4.65M | -140.18%-2.87M | -84.95%-8.14M | -98.22%-5.89M | -61.20%-2.73M | -334.26%-1.2M | -197.77%-4.4M |
| -Interest expense (Financial expense) | -37.36%69.05K | -32.53%290.93K | -53.71%188.57K | -46.00%161.84K | -15.07%110.23K | 21.30%431.2K | 255.18%407.4K | 51.28%299.69K | 74.85%129.79K | --355.47K |
| -Interest Income (Financial expense) | 81.02%-484.96K | 24.56%-6.58M | -6.25%-5.95M | -59.15%-4.84M | -88.67%-2.56M | -106.18%-8.72M | -124.06%-5.6M | -54.72%-3.04M | -478.35%-1.35M | ---4.23M |
| Research and development | -18.95%8.25M | -4.79%39.17M | 0.98%30M | 11.19%20.68M | 19.46%10.18M | 20.31%41.14M | 13.87%29.7M | 26.76%18.6M | 17.21%8.52M | 29.91%34.19M |
| Credit Impairment Loss | 78.40%-91.92K | -2,609.44%-17.07M | 49.29%-118.23K | -22.02%-268.51K | -34.53%-425.49K | 77.16%-629.91K | 87.29%-233.15K | 89.92%-220.06K | 42.94%-316.27K | -149.72%-2.76M |
| Asset Impairment Loss | -80.05%-643.37K | -113.45%-2.72M | -125.46%-1.93M | -70.43%-1.13M | 33.48%-357.33K | 49.82%-1.28M | -9.53%-853.9K | -72.86%-664.93K | -81.62%-537.19K | -1,177.57%-2.54M |
| Adjustment items of total operating cost | --0.01 | ---- | ---- | ---- | ---- | ---- | --0.01 | ---0.01 | ---- | ---- |
| Other net revenue | ||||||||||
| Fair value change income | 159.09%1.61M | -135.86%-237.26K | 1,191.95%3.66M | 139.04%1.56M | 189.78%620.81K | -32.39%661.64K | ---335.36K | --651.77K | ---691.48K | --978.61K |
| Invest income | 99.25%1.94M | 61.38%11.17M | -45.12%3.62M | -30.20%2.31M | -65.78%974.19K | -17.01%6.92M | -5.07%6.59M | -2.05%3.31M | 287.18%2.85M | 586.95%8.34M |
| Asset deal income | ---- | 354.80%136.35K | ---- | ---- | ---- | -138.54%-53.51K | -139.90%-53.51K | ---- | ---- | -81.79%138.85K |
| Other revenue | -9.43%1.35M | -63.98%6.37M | 241.15%4.46M | 144.44%3.19M | 1,204.55%1.49M | 77.46%17.69M | -81.31%1.31M | -47.49%1.31M | --113.93K | 59.49%9.97M |
| Adjusted Items effecting operating profit | 200.00%0.01 | ---- | ---- | ---- | ---0.01 | ---- | ---- | ---- | ---- | ---- |
| Operating profit | -79.73%683.75K | -368.00%-14.58M | 139.91%4.5M | 130.62%3.92M | 141.26%3.37M | -80.22%5.44M | -136.83%-11.28M | -149.59%-12.82M | -140.76%-8.18M | -61.90%27.51M |
| Add:Non operating Income | 7.14%35.39K | 49.33%202.16K | 12,267,206.21%177.88K | 2,975,650.45%33.03K | --33.03K | 3,197.41%135.38K | -99.97%1.45 | -99.98%1.11 | ---- | -99.35%4.11K |
| Less:Non operating expense | 389.33%164.48K | 2.91%838.78K | -61.02%193.1K | -6.33%140.76K | -77.32%33.61K | -1.77%815.06K | -40.24%495.38K | -50.58%150.27K | --148.21K | 116.82%829.73K |
| Total profit | -83.56%554.66K | -419.61%-15.22M | 138.10%4.49M | 129.43%3.82M | 140.52%3.37M | -82.15%4.76M | -139.51%-11.78M | -150.75%-12.97M | -141.49%-8.32M | -63.17%26.68M |
| Less:Income tax cost | -101.43%-666.27K | -111.89%-7.41M | 94.67%-183.11K | 81.48%-513.99K | 82.88%-330.77K | -204.38%-3.5M | -156.69%-3.44M | -176.47%-2.78M | -159.29%-1.93M | -57.17%3.35M |
| Add:Adjusted items effecting net profit | ---- | ---- | ---- | ---- | ---- | ---- | --0.01 | ---- | ---- | ---- |
| Net profit | -67.04%1.22M | -194.59%-7.81M | 155.99%4.67M | 142.49%4.33M | 157.94%3.7M | -64.60%8.26M | -135.12%-8.34M | -146.50%-10.19M | -138.03%-6.39M | -63.89%23.33M |
| Net profit from continuing operation | -67.04%1.22M | -194.59%-7.81M | 155.99%4.67M | 142.49%4.33M | 157.94%3.7M | -64.60%8.26M | -135.12%-8.34M | -146.50%-10.19M | -138.03%-6.39M | -63.89%23.33M |
| Net profit of parent company owners | -67.04%1.22M | -194.59%-7.81M | 155.99%4.67M | 142.49%4.33M | 157.94%3.7M | -64.60%8.26M | -135.12%-8.34M | -146.50%-10.19M | -138.03%-6.39M | -63.89%23.33M |
| Earning per share | ||||||||||
| Basic earning per share | -66.67%0.03 | -195.24%-0.2 | 157.14%0.12 | 148.00%0.12 | 156.25%0.09 | -66.13%0.21 | -129.58%-0.21 | -139.68%-0.25 | -128.57%-0.16 | -71.16%0.62 |
| Diluted earning per share | -66.67%0.03 | -183.33%-0.2 | 157.14%0.12 | 148.00%0.12 | 156.25%0.09 | -60.66%0.24 | -130.00%-0.21 | -140.32%-0.25 | -128.57%-0.16 | -71.36%0.61 |
| Other composite income | -179.24%-54.42K | -6.53%580.77K | -134.48%-414.68K | -83.84%244.72K | 113.29%68.68K | 228.55%621.35K | 42.82%1.2M | 279.64%1.51M | -2,184.58%-516.67K | -219.53%-483.37K |
| Other composite income of parent company owners | -179.24%-54.42K | -6.53%580.77K | -134.48%-414.68K | -83.84%244.72K | 113.29%68.68K | 228.55%621.35K | 42.82%1.2M | 279.64%1.51M | -2,184.58%-516.67K | -219.53%-483.37K |
| Total composite income | -69.08%1.17M | -181.43%-7.23M | 159.61%4.26M | 152.73%4.58M | 154.60%3.77M | -61.13%8.88M | -129.03%-7.14M | -138.88%-8.68M | -141.16%-6.91M | -64.56%22.85M |
| Total composite income of parent company owners | -69.08%1.17M | -181.43%-7.23M | 159.61%4.26M | 152.73%4.58M | 154.60%3.77M | -61.13%8.88M | -129.03%-7.14M | -138.88%-8.68M | -141.16%-6.91M | -64.56%22.85M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- |
| Auditor | -- | -- | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.